{
    "id": 107,
    "premise": "none",
    "hypothesis": "This patient may develop resistance to Trastuzumab therapy.",
    "label": "entailment",
    "explanation": "overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line.\nA portion of tumours, however, ultimately develop resistance to anti-HER2 antibody therapy.\nPatient may benefit from treatment with Trastuzumab.",
    "results": {
        "semantic validity": true,
        "premise": null,
        "hypothesis": "This patient may develop resistance to Trastuzumab therapy.",
        "refined explanation": "Overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line.\nA portion of tumors in patients ultimately develop resistance to anti-HER2 antibody therapy, including Trastuzumab.\nPatients with tumors that develop resistance to anti-HER2 antibody therapy are likely to develop resistance to Trastuzumab therapy.\nPatients who develop resistance to anti-HER2 antibody therapy may also develop resistance to Trastuzumab therapy.\nPatients may benefit from treatment with Trastuzumab.",
        "refined iteration": 2,
        "history explanation": [
            "0 iteration: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line.\nA portion of tumours, however, ultimately develop resistance to anti-HER2 antibody therapy.\nPatient may benefit from treatment with Trastuzumab.",
            "1 iteration: Overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line.\nA portion of tumours ultimately develop resistance to anti-HER2 antibody therapy, including Trastuzumab.\nPatients who develop resistance to anti-HER2 antibody therapy may also develop resistance to Trastuzumab therapy.\nPatient may benefit from treatment with Trastuzumab.",
            "2 iteration: Overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line.\nA portion of tumors in patients ultimately develop resistance to anti-HER2 antibody therapy, including Trastuzumab.\nPatients with tumors that develop resistance to anti-HER2 antibody therapy are likely to develop resistance to Trastuzumab therapy.\nPatients who develop resistance to anti-HER2 antibody therapy may also develop resistance to Trastuzumab therapy.\nPatients may benefit from treatment with Trastuzumab."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: True"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '(* Explanation 2 states that a portion of tumours ultimately develop resistance to anti-HER2 antibody therapy. *)\\n(* Explanation 3 states that a patient may benefit from treatment with Trastuzumab. *)\\n(* We have a logical relation Implies(Not(C), D), which implies that if tumours do not develop resistance, the patient may benefit from Trastuzumab. *)\\n(* However, we are interested in the case where resistance develops, which is directly stated in Explanation 2. *)\\n(* Therefore, we can infer that the patient may develop resistance to Trastuzumab therapy. *)\\nthen have \"\u2203y e. Resistance y \u2227 TrastuzumabTherapy y \u2227 Develop e \u2227 Agent e x \u2227 Patient e y\" sledgehammer', 'solving time': 104.9359142780304, 'proof tactics': [], 'code': 'theory clinical_107_0\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Overexpression :: \"entity \u21d2 bool\"\\n  HER2V777LMutation :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Assay :: \"entity \u21d2 bool\"\\n  SoftAgarColonyFormation :: \"entity \u21d2 bool\"\\n  CancerCellLine :: \"entity \u21d2 bool\"\\n  Colorectal :: \"entity \u21d2 bool\"\\n  Result :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Method :: \"event \u21d2 entity \u21d2 bool\"\\n  Tumour :: \"entity \u21d2 bool\"\\n  Portion :: \"entity \u21d2 bool\"\\n  AntiHER2AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Develop :: \"event \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Source :: \"event \u21d2 entity \u21d2 bool\"\\n  PatientEntity :: \"entity \u21d2 bool\"  (* Renamed to avoid conflict with Patient event *)\\n  TrastuzumabTherapy :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Overexpression x \u2227 HER2V777LMutation x \u2227 Resistance y \u2227 Trastuzumab y \u2227 Assay z \u2227 SoftAgarColonyFormation z \u2227 CancerCellLine z \u2227 Colorectal z \u2227 Result e \u2227 Agent e x \u2227 Patient e y \u2227 Method e z\"\\n\\n(* Explanation 2: A portion of tumours, however, ultimately develop resistance to anti-HER2 antibody therapy. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e. Tumour x \u2227 Portion x \u2227 Resistance y \u2227 AntiHER2AntibodyTherapy y \u2227 Develop e \u2227 Agent e x \u2227 Patient e y\"\\n\\n(* Explanation 3: Patient may benefit from treatment with Trastuzumab. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y e. PatientEntity x \u2227 Treatment y \u2227 Trastuzumab y \u2227 Benefit e \u2227 Agent e x \u2227 Source e y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"PatientEntity x\"\\n  (* Hypothesis: This patient may develop resistance to Trastuzumab therapy. *)\\n  shows \"\u2203x y e. PatientEntity x \u2227 Resistance y \u2227 TrastuzumabTherapy y \u2227 Develop e \u2227 Agent e x \u2227 Patient e y\"\\nproof -\\n  (* From the premise, we have the known information about the patient entity. *)\\n  from asm have \"PatientEntity x\" <ATP>\\n  (* Explanation 2 states that a portion of tumours ultimately develop resistance to anti-HER2 antibody therapy. *)\\n  (* Explanation 3 states that a patient may benefit from treatment with Trastuzumab. *)\\n  (* We have a logical relation Implies(Not(C), D), which implies that if tumours do not develop resistance, the patient may benefit from Trastuzumab. *)\\n  (* However, we are interested in the case where resistance develops, which is directly stated in Explanation 2. *)\\n  (* Therefore, we can infer that the patient may develop resistance to Trastuzumab therapy. *)\\n  then have \"\u2203y e. Resistance y \u2227 TrastuzumabTherapy y \u2227 Develop e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: overexpression of a HER2 V777L mutation (from Explanatory Sentence 1)\\nB: trastuzumab resistance (from Explanatory Sentence 1)\\nC: tumours develop resistance to anti-HER2 antibody therapy (from Explanatory Sentence 2)\\nD: patient may benefit from treatment with Trastuzumab (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(overexpression of a HER2 V777L mutation, trastuzumab resistance)\\n--------\\nImplies(Not(C), D)\\nImplies(Not(tumours develop resistance to anti-HER2 antibody therapy), patient may benefit from treatment with Trastuzumab)\\n--------\\n\\nDerived Implications:\\n'}",
            "1 iteration: {'syntactic validity': True, 'error code': '(* Explanation 3 states that patients who develop resistance to anti-HER2 antibody therapy may also develop resistance to Trastuzumab therapy. *)\\n(* This is related to logical proposition D: Resistance to Trastuzumab therapy. *)\\n(* Explanation 2 provides the link between tumours developing resistance to anti-HER2 antibody therapy and Trastuzumab. *)\\n(* Using the logical relation Implies(C, D), we can infer that if a patient develops resistance to anti-HER2 antibody therapy, they may develop resistance to Trastuzumab therapy. *)\\nthen have \"\u2203y e. Resistance y \u2227 TrastuzumabTherapy y \u2227 Develop e \u2227 Agent e x \u2227 Patient y\" sledgehammer', 'solving time': 104.09861779212952, 'proof tactics': [], 'code': 'theory clinical_107_1\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Overexpression :: \"entity \u21d2 bool\"\\n  HER2V777LMutation :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Assay :: \"entity \u21d2 bool\"\\n  ColorectalCancerCellLine :: \"entity \u21d2 bool\"\\n  Resulted :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  By :: \"event \u21d2 entity \u21d2 bool\"\\n  Tumour :: \"entity \u21d2 bool\"\\n  AntiHER2AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Develop :: \"event \u21d2 bool\"\\n  TrastuzumabTherapy :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  From :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. Overexpression x \u2227 HER2V777LMutation x \u2227 Resistance y \u2227 Trastuzumab y \u2227 Assay z \u2227 ColorectalCancerCellLine z \u2227 Resulted e1 \u2227 Agent e1 x \u2227 Patient y \u2227 By e2 z\"\\n\\n(* Explanation 2: A portion of tumours ultimately develop resistance to anti-HER2 antibody therapy, including Trastuzumab. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e. Tumour x \u2227 Resistance y \u2227 AntiHER2AntibodyTherapy y \u2227 Trastuzumab y \u2227 Develop e \u2227 Agent e x \u2227 Patient y\"\\n\\n(* Explanation 3: Patients who develop resistance to anti-HER2 antibody therapy may also develop resistance to Trastuzumab therapy. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Patient x \u2227 Resistance y \u2227 AntiHER2AntibodyTherapy y \u2227 TrastuzumabTherapy z \u2227 Develop e1 \u2227 Agent e1 x \u2227 Patient y \u2227 Develop e2 \u2227 Agent e2 x \u2227 Patient z\"\\n\\n(* Explanation 4: Patient may benefit from treatment with Trastuzumab. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y e. Patient x \u2227 Treatment y \u2227 Trastuzumab y \u2227 Benefit e \u2227 Agent e x \u2227 From e y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x\"\\n  (* Hypothesis: This patient may develop resistance to Trastuzumab therapy. *)\\n  shows \"\u2203x y e. Patient x \u2227 Resistance y \u2227 TrastuzumabTherapy y \u2227 Develop e \u2227 Agent e x \u2227 Patient y\"\\nproof -\\n  (* From the premise, we have the known information about the patient. *)\\n  from asm have \"Patient x\" <ATP>\\n  (* Explanation 3 states that patients who develop resistance to anti-HER2 antibody therapy may also develop resistance to Trastuzumab therapy. *)\\n  (* This is related to logical proposition D: Resistance to Trastuzumab therapy. *)\\n  (* Explanation 2 provides the link between tumours developing resistance to anti-HER2 antibody therapy and Trastuzumab. *)\\n  (* Using the logical relation Implies(C, D), we can infer that if a patient develops resistance to anti-HER2 antibody therapy, they may develop resistance to Trastuzumab therapy. *)\\n  then have \"\u2203y e. Resistance y \u2227 TrastuzumabTherapy y \u2227 Develop e \u2227 Agent e x \u2227 Patient y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Overexpression of a HER2 V777L mutation (from Explanatory Sentence 1)\\nB: Trastuzumab resistance in a colorectal cancer cell line (from Explanatory Sentence 1)\\nC: Tumours develop resistance to anti-HER2 antibody therapy (from Explanatory Sentence 2)\\nD: Resistance to Trastuzumab therapy (from Explanatory Sentence 3)\\nE: Patient benefits from treatment with Trastuzumab (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Overexpression of a HER2 V777L mutation, Trastuzumab resistance in a colorectal cancer cell line)\\n--------\\nImplies(C, D)\\nImplies(Tumours develop resistance to anti-HER2 antibody therapy, Resistance to Trastuzumab therapy)\\n--------\\nImplies(Not(D), E)\\nImplies(Not(Resistance to Trastuzumab therapy), Patient benefits from treatment with Trastuzumab)\\n--------\\n\\nDerived Implications:\\n'}",
            "2 iteration: {'syntactic validity': True, 'error code': '', 'solving time': 42.69395065307617, 'proof tactics': ['Sledgehammering...', 'vampire found a proof...', 'vampire: Try this: using explanation_4 by auto (18 ms)', 'e found a proof...', 'e: Found duplicate proof', 'Done'], 'code': 'theory clinical_107_2\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Overexpression :: \"entity \u21d2 bool\"\\n  HER2V777LMutation :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Assay :: \"entity \u21d2 bool\"\\n  SoftAgarColonyFormation :: \"entity \u21d2 bool\"\\n  ColorectalCancerCellLine :: \"entity \u21d2 bool\"\\n  Result :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  AntiHER2AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Develop :: \"event \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  TrastuzumabTherapy :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Source :: \"event \u21d2 entity \u21d2 bool\"\\n  Tumor :: \"entity \u21d2 bool\"\\n  Method :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Overexpression x \u2227 HER2V777LMutation x \u2227 Resistance y \u2227 Trastuzumab y \u2227 Assay z \u2227 SoftAgarColonyFormation z \u2227 ColorectalCancerCellLine z \u2227 Result e \u2227 Agent e x \u2227 Patient y \u2227 Method e z\"\\n\\n(* Explanation 2: A portion of tumors in patients ultimately develop resistance to anti-HER2 antibody therapy, including Trastuzumab. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. Tumor x \u2227 Patient y \u2227 Resistance z \u2227 AntiHER2AntibodyTherapy z \u2227 Trastuzumab z \u2227 Develop e \u2227 Agent e x \u2227 Patient z \u2227 In x y\"\\n\\n(* Explanation 3: Patients with tumors that develop resistance to anti-HER2 antibody therapy are likely to develop resistance to Trastuzumab therapy. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2. Patient x \u2227 Tumor y \u2227 Resistance z \u2227 AntiHER2AntibodyTherapy z \u2227 Develop e1 \u2227 Agent e1 y \u2227 Patient z \u2227 Resistance w \u2227 TrastuzumabTherapy w \u2227 Develop e2 \u2227 Agent e2 x \u2227 Patient w\"\\n\\n(* Explanation 4: Patients who develop resistance to anti-HER2 antibody therapy may also develop resistance to Trastuzumab therapy. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z w e1 e2. Patient x \u2227 Resistance y \u2227 AntiHER2AntibodyTherapy y \u2227 Develop e1 \u2227 Agent e1 x \u2227 Patient y \u2227 Resistance z \u2227 TrastuzumabTherapy z \u2227 Develop e2 \u2227 Agent e2 x \u2227 Patient z\"\\n\\n(* Explanation 5: Patients may benefit from treatment with Trastuzumab. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y e. Patient x \u2227 Treatment y \u2227 Trastuzumab y \u2227 Benefit e \u2227 Agent e x \u2227 Source e y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x\"\\n  (* Hypothesis: This patient may develop resistance to Trastuzumab therapy. *)\\n  shows \"\u2203x y e. Patient x \u2227 Resistance y \u2227 TrastuzumabTherapy y \u2227 Develop e \u2227 Agent e x \u2227 Patient y\"\\nproof -\\n  (* From the premise, we have the known information about the patient. *)\\n  from asm have \"Patient x\" <ATP>\\n  (* Explanation 4 provides a logical relation Implies(C, D), which states that patients who develop resistance to anti-HER2 antibody therapy may also develop resistance to Trastuzumab therapy. *)\\n  (* Since we are trying to prove that this patient may develop resistance to Trastuzumab therapy, we can use this logical relation. *)\\n  (* Explanation 4 directly supports the hypothesis that a patient may develop resistance to Trastuzumab therapy. *)\\n  then have \"\u2203y z e1 e2. Resistance y \u2227 AntiHER2AntibodyTherapy y \u2227 Develop e1 \u2227 Agent e1 x \u2227 Patient y \u2227 Resistance z \u2227 TrastuzumabTherapy z \u2227 Develop e2 \u2227 Agent e2 x \u2227 Patient z\" <ATP>\\n  (* From this, we can infer the existence of resistance to Trastuzumab therapy for the patient. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Overexpression of a HER2 V777L mutation (from Explanatory Sentence 1)\\nB: Trastuzumab resistance in a colorectal cancer cell line (from Explanatory Sentence 1)\\nC: Tumors develop resistance to anti-HER2 antibody therapy (from Explanatory Sentence 2)\\nD: Resistance to Trastuzumab therapy (from Explanatory Sentence 3 and 4)\\nE: Patients benefit from treatment with Trastuzumab (from Explanatory Sentence 5)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Overexpression of a HER2 V777L mutation, Trastuzumab resistance in a colorectal cancer cell line)\\n--------\\nImplies(C, D)\\nImplies(Tumors develop resistance to anti-HER2 antibody therapy, Resistance to Trastuzumab therapy)\\n--------\\nImplies(D, D)\\nTrue\\n--------\\nImplies(Not(D), E)\\nImplies(Not(Resistance to Trastuzumab therapy), Patients benefit from treatment with Trastuzumab)\\n--------\\n\\nDerived Implications:\\n'}"
        ]
    }
}